This observational study evaluated the performance of new lab tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately. 19 NICHD Neonatal Research Network sites enrolled 1,500 infants with birth weights ≤1,000g; 100 of these infants later tested positive for candidiasis. Blood, urine, and lumbar puncture samples were collected whenever other specimens were obtained from participants for cultures. These samples are being tested using the new methods and compared with standard culture results. Surviving study subjects completed a neurodevelopmental evaluation at 18-22 months corrected age.
Candida species are a leading cause of infectious mortality in newborns with the incidence rates estimated at 4-18% in extremely low birth weight (ELBW) infants. 20-30% of these infants are likely to die. Because candida can invade virtually all body tissues (eyes, brain, heart, lung, liver, spleen, urinary tract, and joints), survivors of invasive Candida infections are at risk of blindness, developmental delays, and the need for surgical and other corrective procedures. Time is of the essence in detecting and treating these infections, with infant mortality from candidiasis largely attributed to duration of time for cultures to become positive for Candida. Diagnosis of candidiasis is challenging - blood and urine tests are slow (taking up to 72 hours to complete) and inaccurate in many cases, showing negative results despite overwhelming disease in adults as well as children. These problems are likely made worse in neonates, with smaller amounts of blood available for testing and infections that often spread to tissues inaccessible for testing. This observational study is evaluating the performance of new lab tests (beta-glucan assays, Gas Chromatography Mass Spectrometry for D-arabinitol, and polymerase chain reaction tests) compared to existing culture tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately. In this study, 19 NICHD Neonatal Research Network sites enrolled 1,500 infants with birth weights ≤1,000g by 72 hours of life; more than 100 of these infants later tested positive for candidiasis. In the larger cohort, whenever cultures of blood or urine were obtained, or a lumbar puncture was done, additional samples and clinical data were collected. These additional samples are being tested using the new techniques under investigation. No additional blood specimens were taken once participants had a positive blood culture for candida. Note: Test procedure reagents are being provided the Duke University laboratory by Cape Cod Incorporated and Rockeby; the Thrasher Research Fund is also providing support to the Duke University laboratory. Surviving study subjects completed a neurodevelopmental evaluation at 18-22 months corrected age to evaluate potential early risk factors with long-term outcome.
Study Type
OBSERVATIONAL
Enrollment
1,500
University of Alabama at Birmingham
Birmingham, Alabama, United States
Stanford University
Palo Alto, California, United States
University of California at San Diego
San Diego, California, United States
Yale University
New Haven, Connecticut, United States
University of Miami
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Indiana University
Indianapolis, Indiana, United States
University of Iowa
Iowa City, Iowa, United States
Tufts Medical Center
Boston, Massachusetts, United States
Wayne State University
Detroit, Michigan, United States
...and 10 more locations
Probability of invasive candidiasis based on new assay results
Time frame: Until discharge
Determine test performance of clinical predictive model
Time frame: Until discharge
Determine test performance (sensitivity and specificity) of polymerase chain reaction (PCR) testing
Time frame: Until discharge
Determine test performance of Beta-glucan assay
Time frame: Until discharge
Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of blood samples
Time frame: Until discharge
Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of urine samples
Time frame: Until discharge
Determine test performance of the blood culture
Time frame: Until discharge
Determine test performance of the lumbar puncture (cell count, protein, glucose, and culture)
Time frame: Until discharge
Determine test performance of tracheal aspirates
Time frame: Until discharge
Determine test performance of urine cultures
Time frame: Until discharge
Compare clinical predictive model performance to neonatologist clinical judgment
Time frame: Until discharge
Determine incidence of end-organ damage in neonates with candidemia
Time frame: Until discharge
Determine resistance patterns of organisms isolated
Time frame: Until discharge
Determine molecular epidemiology of candidemia
Time frame: Until discharge
Determine genetic expression of organism virulence factors
Time frame: Until discharge
Neurodevelopmental outcome
Time frame: 18-22 months corrected age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.